Risk On Prior to 2020’s black swan (low probability/high impact) event of the COVID-19 outbreak and subsequent shutdown of the economy, your clients had the luxury of being in a position to care less about volatility and risk exposure and only about the end result....
The Drug-making titans are up in arms about the proposals to reduce their pricing power, ultimately cutting into their sales by the billions. There has been an increased concern of the ever-rising drug prices, and action against it has started.
With Everlong, you are never at the mercy of these industry prices. Learn more about how Everlong stays ahead of the curve with our cost-saving solutions.
Contact us to learn more.
Drugmakers, Worried About Losing Pricing Power, Are Lobbying Hard
The Wall Street Journal
“Industry executives and lobbyists are urging friendly lawmakers to pass legislation blocking the plans. They are also pushing administration officials to pursue measures that would pressure industry middlemen such as pharmacy-benefit managers to provide some relief on patients’ costs without directly curbing drugmakers’ pricing power.”
“The Trump administration last October proposed basing how much Medicare pays for cancer, eye and certain other drugs on the prices charged in other countries, including in Europe, where drugs are less expensive.”
The Everlong Difference (Part 4): Invest More in What Works, Divest from the Rest In today’s economy, the allocation of resources provides little margin for error. It’s no longer sufficient to invest in what’s working today, you must also be able leverage analytical...
The Everlong Difference (Part 3): Use Positive Peer Pressure to Your Advantage We’ve all heard that peer pressure is “bad” and although that’s arguably true, there is new research that indicates how positive peer pressure creates a social advantage. And within the...